HFZS
839725
GLORIA
831641
Y&J CO.,LTD.
833943
COCYBER
835207
Sichuan Etrol Technologies
300370
CN Stock MarketDetailed Quotes
688163 Shanghai Serum Bio-Technology
- 21.75
- -0.85-3.76%
Market Closed Dec 3 15:00 CST
2.35BMarket Cap46.18P/E (TTM)
22.59High21.59Low47.87KlotVolume22.59Open22.60Pre Close105.24MTurnover10.79%Turnover Ratio60.75P/E (Static)108.22MShares22.9252wk High2.11P/B965.09MFloat Cap10.6652wk Low27.12Limit Up44.37MShs Float61.02Historical High18.08Limit Down4.43%Amplitude10.66Historical Low0.32Dividend TTM21.99Avg Price26.50KlotAsk1.47%Div YieldTTM100Lot Size18.96KlotBid
Shanghai Serum Bio-Technology Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 4.31%173.29M | 4.58%98.06M | 9.79%26.3M | 9.14%190.14M | 11.17%166.13M | 19.88%93.76M | -3.80%23.96M | -16.52%174.22M | -11.04%149.43M | -18.46%78.21M |
| Operating revenue | 4.31%173.29M | 4.58%98.06M | 9.79%26.3M | 9.14%190.14M | 11.17%166.13M | 19.88%93.76M | -3.80%23.96M | -16.52%174.22M | -11.04%149.43M | -18.46%78.21M |
| Total operating cost | -3.45%107.9M | 1.86%68.03M | 17.63%28.35M | 29.48%150.18M | 27.56%111.75M | 34.43%66.79M | 13.69%24.1M | -6.04%115.98M | 2.56%87.61M | -1.68%49.68M |
| Operating cost | -4.33%36.68M | -1.66%22.98M | 2.85%7.51M | 63.34%46.19M | 63.72%38.34M | 98.75%23.37M | 73.91%7.3M | -16.97%28.28M | -11.64%23.42M | -22.70%11.76M |
| Operating tax surcharges | 8.39%1.31M | 5.34%796.69K | 11.67%326.14K | 26.89%1.53M | 16.56%1.21M | 10.57%756.3K | -39.43%292.05K | -16.84%1.21M | -6.13%1.04M | -0.20%684.03K |
| Operating expense | 6.33%39.32M | -9.39%22.28M | -2.92%9.58M | 7.10%53.84M | 1.10%36.98M | 22.31%24.59M | 3.53%9.87M | 15.84%50.27M | 27.47%36.58M | 25.60%20.1M |
| Administration expense | 5.43%15.84M | -1.11%10.49M | 26.74%5.25M | -12.49%20.51M | -22.47%15.02M | -19.40%10.61M | -6.45%4.14M | 20.74%23.44M | 32.57%19.37M | 57.03%13.17M |
| Financial expense | 25.64%-1.42M | 40.39%-919.05K | 33.72%-512.43K | 13.59%-2.31M | 18.20%-1.91M | 15.40%-1.54M | 11.34%-773.14K | -319.29%-2.67M | -402.84%-2.34M | -495.67%-1.82M |
| -Interest expense (Financial expense) | -27.29%355K | -5.08%311.59K | -5.08%155.79K | -4.73%648.26K | -4.70%488.25K | -4.63%328.25K | -4.63%164.12K | -4.24%680.46K | -4.17%512.31K | -4.05%344.16K |
| -Interest Income (Financial expense) | 19.10%-1.8M | 25.95%-1.22M | 33.71%-657.73K | -0.37%-2.88M | 1.21%-2.23M | 12.80%-1.65M | 3.27%-992.25K | -93.37%-2.87M | -116.15%-2.26M | -161.07%-1.89M |
| Research and development | -26.87%16.17M | 37.72%12.4M | 89.35%6.2M | 96.75%30.41M | 131.84%22.11M | 55.46%9M | -4.65%3.28M | -40.00%15.46M | -36.28%9.54M | -45.10%5.79M |
| Credit Impairment Loss | 18.66%-1.61M | 34.82%-1.67M | -278.74%-637.25K | -289.79%-997.07K | -2,066.27%-1.98M | -314.39%-2.56M | 148.79%356.53K | 187.37%525.35K | 87.60%-91.4K | 71.10%-616.94K |
| Asset Impairment Loss | -37.89%-3.94M | 58.08%-907.99K | 66.22%-365.01K | 30.04%-3.65M | 4.04%-2.86M | -10.32%-2.17M | -185.04%-1.08M | -129.69%-5.22M | -43.86%-2.98M | -31.47%-1.96M |
| Other net revenue | ||||||||||
| Fair value change income | -51.89%1.5M | -48.59%1.97M | 37.44%2.26M | -0.95%2.59M | -3.58%3.12M | 57.64%3.84M | 618.75%1.64M | 1,657.53%2.62M | 1,339.55%3.24M | 1,415.09%2.44M |
| Invest income | 33.23%7.95M | 6.95%4.36M | -75.74%645.46K | -42.32%7.74M | -29.99%5.97M | -1.76%4.07M | 3,379.76%2.66M | 1,534.66%13.43M | 1,240.96%8.53M | 695.53%4.15M |
| -Including: Investment income associates | 57.04%-2.3M | 12.41%-1.7M | -68.36%-990.43K | -198.38%-7.35M | -257.46%-5.36M | -386.76%-1.94M | -47.79%-588.29K | 8.73%-2.46M | 10.60%-1.5M | 63.57%-397.7K |
| Asset deal income | --1.44M | ---- | ---- | ---- | ---- | --11.92K | ---- | ---- | ---- | ---- |
| Other revenue | 1,330.26%3.55M | 1,377.01%3.45M | 1,160.60%2.08M | -93.47%331.53K | -91.65%248.16K | -91.89%233.53K | 327.17%164.75K | -23.28%5.08M | -34.63%2.97M | -18.16%2.88M |
| Operating profit | 26.16%74.29M | 22.44%37.23M | -46.31%1.94M | -38.41%45.98M | -19.88%58.88M | -14.12%30.41M | -18.68%3.6M | -15.36%74.66M | -12.26%73.49M | -20.86%35.41M |
| Add:Non operating Income | -25.21%9.83K | 10,630,000.00%1.06K | ---- | -81.99%13.15K | -81.99%13.15K | -100.00%0.01 | ---- | -27.44%73K | --73K | --73K |
| Less:Non operating expense | 307.50%665.12K | 274.76%179.14K | --19.1K | -16.52%581.86K | -59.54%163.22K | -70.12%47.8K | ---- | 61.00%697.02K | 23.46%403.4K | -25.27%160K |
| Total profit | 25.36%73.63M | 22.04%37.05M | -46.84%1.92M | -38.66%45.42M | -19.72%58.73M | -14.05%30.36M | -18.50%3.6M | -15.75%74.04M | -12.31%73.16M | -20.68%35.32M |
| Less:Income tax cost | 34.61%10.68M | 37.47%4.75M | -25.12%441.49K | -32.51%6.64M | -23.63%7.94M | -28.98%3.45M | 27.39%589.63K | -13.64%9.84M | -7.85%10.39M | -11.57%4.86M |
| Net profit | 23.92%62.95M | 20.06%32.31M | -51.09%1.47M | -39.60%38.77M | -19.07%50.8M | -11.67%26.91M | -23.86%3.02M | -16.06%64.2M | -13.01%62.77M | -21.96%30.46M |
| Net profit from continuing operation | 23.92%62.95M | 20.06%32.31M | -51.09%1.47M | -39.60%38.77M | -19.07%50.8M | -11.67%26.91M | -23.86%3.02M | -16.06%64.2M | -13.01%62.77M | -21.96%30.46M |
| Net profit of parent company owners | 23.92%62.95M | 20.06%32.31M | -51.09%1.47M | -39.60%38.77M | -19.07%50.8M | -11.67%26.91M | -23.86%3.02M | -16.06%64.2M | -13.01%62.77M | -21.96%30.46M |
| Earning per share | ||||||||||
| Basic earning per share | 23.40%0.58 | 20.00%0.3 | -66.67%0.01 | -42.86%0.36 | -25.40%0.47 | -21.88%0.25 | -25.00%0.03 | -32.98%0.63 | -29.21%0.63 | -33.33%0.32 |
| Diluted earning per share | 23.40%0.58 | 20.00%0.3 | -66.67%0.01 | -42.86%0.36 | -25.40%0.47 | -21.88%0.25 | -25.00%0.03 | -32.98%0.63 | -29.21%0.63 | -33.33%0.32 |
| Other composite income | ||||||||||
| Total composite income | 23.92%62.95M | 20.06%32.31M | -51.09%1.47M | -39.60%38.77M | -19.07%50.8M | -11.67%26.91M | -23.86%3.02M | -16.06%64.2M | -13.01%62.77M | -21.96%30.46M |
| Total composite income of parent company owners | 23.92%62.95M | 20.06%32.31M | -51.09%1.47M | -39.60%38.77M | -19.07%50.8M | -11.67%26.91M | -23.86%3.02M | -16.06%64.2M | -13.01%62.77M | -21.96%30.46M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- | -- | -- |
| Auditor | -- | -- | -- | Tianji International Accounting Firm (Special General Partnership) | -- | -- | -- | Tianji International Accounting Firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
